Bicara Q1 net loss $56.2M; cash $539.8M; appoints new CMO and CCO; advances ficerafusp alfa

Bicara Therapeutics Inc.

2026-Q1 EPS reported -$0.93

Net loss of $56.2M for Q1 2026 vs $36.8M YoY; R&D expenses $47.5M, G&A $12.7M.
Cash and marketable securities $539.8M at March 31, 2026; raised ~$161.8M in public offering.
Bill Schelman promoted to CMO; David Raben transitions to Senior Executive Advisor; Chris Sarchi appointed CCO.
Plan to initiate randomized study of ficerafusp alfa + pembrolizumab with loading and Q3W maintenance in 1L R/M HPV-negative HNSCC in Q3 2026.
FORTIFI-HN01 pivotal trial substantially enrolled by year-end; interim analysis mid-2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bicara Therapeutics Inc. reported the first quarter ended March 31, 2026 results: net income Net loss totaled $56.2 million for the first quarter of 2026.

Period: the first quarter ended March 31, 2026
Net income: Net loss totaled $56.2 million for the first quarter of 2026
Result: reported results

Exact text from the filing

Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026

View on SEC.gov

Browse all earnings releases →

Bicara Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-033135

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.